ClinicalTrials.gg
CompletedNCT02835508Updated Jan 11, 2017

Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants

A Phase 1 interventional study of JNJ-56021927 60 Milligram and JNJ-56021927 120 Milligram in Healthy, sponsored by Janssen Pharmaceutical K.K.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-11.

Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
Male
01

Study summary

The purpose of the study is to assess the safety and Pharmacokinetic (PK) profile of JNJ-56021927 and its active metabolite JNJ-56142060 after single-dose administration of 60 milligram (mg), 120 mg, and 240 mg JNJ-56021927 as the tablet formulation in healthy male Japanese participants.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Janssen Pharmaceutical K.K. is the lead sponsor of 126 studies on the registry; none are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have a between 18.0 and 29.9 Kilogram per meter square (kg/m\^2), inclusive, and a body weight not less than 50 Kilogram (kg)
  • Participant must have a blood pressure between 90 and 140 Millimeters of Mercury (mm Hg) systolic, inclusive, and no higher than 90 mm Hg diastolic at screening
  • Participant must have a normal 12-lead (ECG) (based on the mean value of the triplicate parameters) consistent with normal cardiac conduction and function at screening, including: a) normal sinus rhythm (heart rate between 45 and 90 beats per minute, extremes included); b) corrected for heart rate according to Fridericia (QTcF) \<= 450 milliseconds (ms); c) QRS interval less than or equal (\<=)110 ms; d) PR interval \<200 ms; e) ECG morphology consistent with healthy cardiac conduction and function
  • Participant must be a healthy Japanese male
  • Participant must agree to use an adequate method as deemed appropriate by the investigator; to always use a condom during intercourse and to not donate sperm during the study and for 3 months after study drug administration

Exclusion criteria

Exclusion Criteria:

  • Participant with a history of current medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, hepatic or renal insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results
  • Participant has donated blood or blood product or had substantial loss of blood more than 200 milliliter (mL) within 1 month before study drug administration, or greater than equal (>=) 400 mL within 3 months before study drug administration, or participant has donated a total volume of blood in the past one year exceeding 1200 mL, or participant has an intention to donate blood or blood products during the study and for at least 2 months after completion of the study
  • Participant has presence of sexual dysfunction (abnormal libido, erectile dysfunction, etc) or any medical condition that would affect sexual function
  • Participant has received an drug including investigational vaccines or used an invasive investigational medical device within 3 months or within a period less than 10 times the drug's half-life, whichever is longer, before the planned study drug administration
  • Participant has a history of surface antigen (HBsAg) or antibody (anti-hepatitis C virus {HCV}) positive, or other clinically active liver disease, or tests positive for HBsAg or anti-HCV at screening
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Treatment A

    Participants will receive a single dose of 1 tablet of JNJ-56021927, 60 milligram (mg) on Day 1.

    Drug: JNJ-56021927 60 Milligram

  • Experimental
    Treatment B

    Participants will receive a single dose of JNJ-56021927, 120 mg (2 tablets\*60 mg) on Day 1.

    Drug: JNJ-56021927 120 Milligram

  • Experimental
    Treatment C

    Participants will receive a single dose of JNJ-56021927, 240 mg (4 tablets\*60 mg) on Day 1.

    Drug: JNJ-56021927 240 Milligram

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Maximum observed plasma concentration (Cmax) will be assessed.

    Time frame: Predose, Up to Day 57

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Actual sampling time to reach maximum observed analyte concentration (Tmax) will be assessed.

    Time frame: Predose, Up to Day 57

  3. Area Under Concentration from time zero to the last quantifiable AUC (0-last)

    AUC from time zero to the last quantifiable concentration will be assessed.

    Time frame: Predose, Up to Day 57

  4. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity])

    The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC (0-last) and C (0-last)/lambda(z); wherein AUC (0-last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda (z) is elimination rate constant. AUC (0-infinity) will be assessed.

    Time frame: Predose, Up to Day 57

  5. Time to Last Quantifiable Plasma Concentration (Tlast)

    The Tlast, time to last observed quantifiable plasma concentration will be assessed.

    Time frame: Predose, Up to Day 57

  6. Percentage of Area Under the Plasma Concentration-Time Curve Extrapolated From Last Measurable Concentration to Infinite Time (%AUC,ext)

    Percentage of area under the plasma concentration-time curve extrapolated from last measurable concentration to infinite time (%AUC,ext) is calculated as (AUC \[0-infinity\] minus AUC \[0-last\])/ AUC \[0-infinity\])\*100.

    Time frame: Predose, Up to Day 57

  7. Apparent Clearance (CL/F)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. CL/F will be calculated as CL/F = Dose/AUC \[0-infinity\]

    Time frame: Predose, Up to Day 57

  8. Apparent Terminal Elimination Half-life (t1/2term)

    Apparent terminal elimination half-life, calculated as 0.693/apparent terminal elimination rate constant (λz)

    Time frame: Predose, Up to Day 57

  9. Apparent Terminal Elimination Rate Constant (lambda z)

    Apparent terminal elimination rate constant, estimated by linear regression using the terminal log-linear phase of the log transformed concentration vs time data

    Time frame: Predose, Up to Day 57

  10. Apparent Volume of Distribution (Vd/F)

    Apparent volume of distribution based on the terminal phase following oral administration calculated as Vd/F = Dose/ apparent terminal elimination rate constant (λz)\*AUC \[0-infinity\]

    Time frame: Predose, Up to Day 57

  11. Metabolite to Parent Drug Ratio for Maximum Observed Plasma Concentration (MPR Cmax)

    Metabolite to parent drug ratio for Cmax will be assessed.

    Time frame: Predose, Up to Day 57

  12. Metabolite to Parent Drug Ratio for Area Under Concentration from time zero to the last quantifiable concentration (MPR AUC [0-last])

    Metabolite to parent drug ratio for AUC \[0-last\] will be assessed.

    Time frame: Predose, Up to Day 57

  13. Metabolite to Parent Drug Ratio for Area Under Curve from time zero extrapolated to infinity (MPR AUC [0-infinity])

    Metabolite to parent drug ratio for AUC \[0-infinity\] will be assessed.

    Time frame: Predose, Up to Day 57

  14. Area Under Curve from time of administration to 24 hours post dosing

    AUC from time of administration to 24 hours post dosing will be assessed.

    Time frame: Predose, Up to Day 57

  15. Area Under Curve from time of administration to 168 hours post dosing

    AUC from time of administration to 168 hours post dosing will be assessed.

    Time frame: Predose, Up to Day 57

Secondary outcomes

  1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability

    Time frame: Up to Day 57

07

Study locations

1 site
  • Kumamoto-Shi, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2016
First posted
Jul 18, 2016
Start
Jun 2016
Primary completionActual
Dec 2016
CompletionActual
Dec 2016
Last update
Jan 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02835508
Responsible party
Sponsor
First posted
Jul 18, 2016
Start date
Jun 2016
Primary completion
Dec 2016
Completion
Dec 2016
Last update
Jan 11, 2017

Study contacts

Janssen Pharmaceutical K.K. Clinical Trial
study director · Janssen Pharmaceutical K.K.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apalutamide

Start the discussion